Table of Contents
EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor insight into the disease market
- Related reports
- Upcoming related reports
MARKET DEFINITION
- Market definition for this report
- Biologic therapies
- Systemic immunomodulators
- Topical corticosteroids
- Topical vitamin derivatives
- Other
- Indication split methodology
- Country coverage
MARKET OVERVIEW
- Seven major markets
- Current and future market overview
- Seven major psoriasis market will grow from $2.5 billion in 2008 to $3.5
billion in 2018
- US
- Current and future market assessment
- Opportunities and threats
- Japan
- Current and future market assessment
- Opportunities and threats
- Five major European markets (5EU)
- Current and future market assessment
- Opportunities and threats
- European trends
- Germany, Italy: topical vitamin derivative license expiries loom
- UK: NICE guidance slows uptake of biologics for psoriasis
- Rest of the world snapshot
- Current market assessment
BRAND DYNAMICS
- Overview of competitive landscape
- Patient acquisition process
- Introduction
- Patient care path
- Points of influence in the patient care path
- Drivers of brand choice
- Disease modification and long-term efficacy drive prescribing
- Efficacy and safety are important to all classes
- US pricing and reimbursement status for leading brands
- Trends in marketing strategies
- Marketing strategy for leading brands
- Sponsorship/disease awareness campaigns
- Direct-to-consumer advertising
- Overview of biologics in psoriasis
- The anti-TNF class dominates biological therapy for psoriasis
- Enbrel (etanercept; Amgen, Pfizer/Wyeth, Takeda)
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Humira (adalimumab; Abbott, Eisai)
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Remicade (infliximab; Centocor Ortho Biotech, Merck/Schering-Plough and
Mitsubishi Tanabe)
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Raptiva (efalizumab; Genentech, Merck Serono)
- Drug profile
- The aftermath of Raptiva' s withdrawal
- Stelara (ustekinumab; Centocor Ortho Biotech, Janssen-Cilag)
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Dovonex (calcipotriol; Leo Pharma, Warner Chilcott, Intendis Torii and
Teikoku Medix)
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Dovobet (calcipotriol/betamethasone; Leo Pharma, Warner Chilcott, Intendis)
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Silkis/Vectical (calcitriol; Galderma)
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Additional brands
- Olux/Olux-E (clobetasol; Stiefel/GlaxoSmithKline)
- Clobex (clobetasol propionate; Galderma)
- Soriatane/Neotigason (acitretin; Roche, Actavis, Stiefel/GlaxoSmithKline)
KEY DEVELOPERS
- Strategic overview
- Recent strategic partnerships and deals
- Pfizer and Wyeth
- GlaxoSmithKline and Stiefel
- Merck and Schering-Plough
- Company strategies in psoriasis
- Big Pharma-backed biologics create a competitive atmosphere, but
psoriasis is not the top earner
- Topical treatments employ a number of strategies to varying success
CASE STUDIES
- Potential impact of biosimilars in the US
- Base case: biosimilar impact from 2014
- Scenario A: price cuts to innovative biologics but no biosimilars in the
next 10 years
- Scenario B: 20% price cut and moratorium on price increases from 2014
with biosimilars launch in 2018
- Scenario C: biosimilars launch in 2018, without interim action by US
payers
BIBLIOGRAPHY
- Journal papers
- Others
- Conference papers
- Websites
- Other sources
- Datamonitor reports
APPENDIX A
- Data definitions, limitations and assumptions
- Standard units
- Lining out of branded products in the forecast versus ‘all others'
- Diagnosis values for topical products
- Assumptions regarding biosimilars
- Derivation of sales forecasts and pricing trends
APPENDIX B
TABLES
- Table: Dermatologist breakdown by region for IMS Prescribing Insights
data, 2008
- Table: Sales and growth of drug classes and brands for psoriasis in the
seven major markets, 2008- 2018
- Table: Key events impacting the psoriasis market, 2009- 2018
- Table: Psoriasis volume and volume growth for the major drug classes for
psoriasis in the seven major markets, 2008- 2018
- Table: Sales forecasts for psoriasis in the seven major markets ($m),
2008- 2018
- Table: Sales and growth of drug classes and brands for psoriasis in the
US, 2008- 2018
- Table: Sales forecasts for psoriasis in the US ($m), 2008- 2018
- Table: Summary of opportunities and threats in the psoriasis market in the
US, 2009
- Table: Sales and growth of drug classes and brands for psoriasis in Japan,
2008- 2018
- Table: Sales forecasts for psoriasis in Japan ($m), 2008- 2018
- Table: Summary of opportunities and threats in the psoriasis market in
Japan, 2009
- Table: Sales and growth of drug classes and brands for psoriasis in the
five major EU markets, 2008- 2018
- Table: Sales forecasts for psoriasis in the five major EU markets ($m),
2008- 2018
- Table: Summary of opportunities and threats for psoriasis in the five
major European markets, 2009
- Table: Comparison of leading branded drug sales ($m) for psoriasis in the
seven major markets and the rest of the world (ROW), 2008
- Table: Leading branded drug sales for psoriasis in the seven major
markets, by class ($m), 2008- 2018
- Table: Dermatologists surveyed regarding psoriasis, 2008
- Table: Comparison of PASI 50, -75 and -90 scores among the biologic brands
- Table: Comparative importance of factors affecting dermatologists'
prescribing decisions for topical vitamin derivatives by country, points out
of 100, 2008
- Table: Representative formulary tier status in the US for leading brands
in psoriasis, 2009
- Table: Marketing strategies employed by the companies behind the top two
biologics for psoriasis, 2009
- Table: Tuberculosis post-marketing data for TNF inhibitors (rheumatoid
arthritis), 2008
- Table: Enbrel - drug profile, 2009
- Table: Comparative efficacy of Enbrel (etanercept) and Raptiva
(efalizumab) in psoriasis, 2004
- Table: Comparative cost per QALY of Enbrel (etanercept) and Raptiva
(efalizumab) in psoriasis in the UK, 2004
- Table: Humira (adalimumab) - drug profile, 2009
- Table: Selected recent Humira (adalimumab) trials in psoriasis, 2009
- Table: Remicade - drug profile, 2009
- Table: Selected recent Remicade (infliximab) trials in psoriasis, 2009
- Table: Raptiva (efalizumab) - drug profile, 2009
- Table: Stelara (ustekinumab) - drug profile, 2009
- Table: Projected pricing for Stelara (ustekinumab) based on relative
pricing of Humira compared to Germany, 2009 ($/SU)
- Table: Dovonex (calcipotriol) - drug profile, 2008
- Table: Dovobet (calcipotriol/betamethasone) - drug profile, 2009
- Table: Silkis/Vectical (calcitriol) - drug profile, 2009
- Table: Olux (clobetasol) - drug profile, 2009
- Table: Olux-E/Olux-E Complete (clobetasol) - drug profile, 2009
- Table: Clobex (clobetasol propionate) - drug profile, 2009
- Table: Soriatane/Neotigason (acitretin) - drug profile, 2009
- Table: Leading companies in the seven major market for psoriasis-specific
sales, 2008- 2018
- Table: Comparative price ($ per patient year) of topical treatments by
formulation, 2008
- Table: Potential scenarios for US biosimilar entry
- Table: Base case forecast impact of biosimilars by country
FIGURES
- Figure: Psoriasis sales by drug class in the seven major markets ($m),
2005- 08
- Figure: Key events impacting the psoriasis market, 2005- 09
- Figure: Psoriasis-specific value ($m) and volume (SU/dose/year) by class,
2008 and 2018
- Figure: Psoriasis sales by drug class in the US ($m), 2005- 08
- Figure: Psoriasis sales by drug class in Japan ($m), 2005- 08
- Figure: Price per standard unit ($/SU) for Remicade (infliximab) in Japan,
Q1 2007- Q2 2008
- Figure: Psoriasis sales by drug class in the five major EU markets ($m),
2005- 08
- Figure: Effect of expiration of distribution agreement between Schering
(now Intendis) and Leo Pharma on the Psorcutan Beta and Dovobet brands of
calcipotriol/betamethasone topical combinations for psoriasis in Germany ($m),
2005- 2018f
- Figure: Effect of expiration of distribution agreement between Schering
(now Intendis) and Leo Pharma on the Token (Psorcutan Beta) and Dovobet brands
of calcipotriol/betamethasone topical combinations for psoriasis in Italy
($m), 2005- 2018f
- Figure: Psoriasis sales ($m) and growth of biologics in the five major EU
markets, 2005- 08
- Figure: Global psoriasis sales breakdown, 2008
- Figure: Annual estimated psoriasis sales outside the seven major markets,
2005- 08
- Figure: Psoriasis patient path
- Figure: Mean non-pharmacological and pharmacological treatment rates in
psoriasis across the seven major markets, 2008
- Figure: Drivers of brand choice for psoriasis, 2009
- Figure: Comparative importance of factors affecting dermatologist
prescribing decisions by class across the seven major markets, 2008
- Figure: Screenshot of Humira of patient assistance program targeting all
patients
- Figure: Screenshot of Enbrel patient assistance program targeting all
patients
- Figure: Screenshot of LeAnn Rimes' story, www.stophiding.org
- Figure: Screenshot of advertising information, www.psoriasis.org
- Figure: Biologics launch dates, by indication, across the seven major
markets, 1998- 2009
- Figure: Enbrel (etanercept) SWOT analysis, 2009
- Figure: Enbrel (etanercept) psoriasis sales by country across the seven
major markets ($m), 2008- 2018
- Figure: Abbott Humira advertisement in American Academy of Dermatology
Post-Meeting News, 2008
- Figure: Humira (adalimumab): SWOT analysis, 2009
- Figure: Humira (adalimumab) psoriasis sales by country across the seven
major markets ($m), 2008- 2018
- Figure: Remicade SWOT analysis, 2009
- Figure: Remicade (infliximab) psoriasis sales by country across the seven
major markets ($m), 2008- 2018
- Figure: Datamonitor estimated biologic market share, 2008 and 2010
- Figure: Apotheke.de screenshot showing the price of Stelara
- Figure: Stelara (ustekinumab) SWOT analysis, 2009
- Figure: Stelara (ustekinumab) psoriasis sales by country, across the seven
major markets ($m), 2008- 2018
- Figure: Dovonex (calcipotriol) SWOT analysis
- Figure: Dovonex (calcipotriol) psoriasis sales by country across the seven
major markets ($m), 2008- 2018
- Figure: Dovobet (calcipotriol/betamethasone) SWOT analysis, 2009
- Figure: Dovobet (calcipotriol/betamethasone) psoriasis sales by country in
the US and 5EU ($m), 2008- 2018
- Figure: Vectical brand website with "Choose Vectical" rationale, Galderma
US, 2009
- Figure: Vectical trial comparisons, Vectical brand website, Galderma US,
2009
- Figure: Splash page, Vectical brand website, Galderma US, 2009
- Figure: Vectical brand website outlining regime Galderma USA, 2009
- Figure: Silkis/Vectical (calcitriol) SWOT analysis, 2009
- Figure: Silkis/Vectical (calcitriol) psoriasis sales in the US and 5EU
($m), 2008- 2018
- Figure: Olux brand website, Stiefel Laboratories, 2009
- Figure: Olux/Olux-E (clobetasol) psoriasis sales by country, in the US, UK
and Italy ($m), 2008- 2018
- Figure: Clobex (clobetasol) psoriasis sales by country in the US and 5EU
($m), 2008- 2018
- Figure: Soriatane/Neotigason (acitretin) psoriasis sales by country in the
US and 5EU ($m), 2008- 2018
- Figure: Pfizer and Wyeth' s company-reported global prescription sales and
Datamonitor forecasts split by therapy area ($m), 2002- 2014
- Figure: Merck and Schering-Plough' s company-reported global prescription
sales and Datamonitor forecasts split by therapy area ($m),, 2002- 2014
- Figure: Psoriasis-specific sales for key biologic brands, in the seven
major markets ($m), 2008- 2018
- Figure: Proportion of total brand sales attributed to psoriasis for key
biologic brands in the seven major markets ($m), 2008 and 2018
- Figure: Importance of Humira within Abbott portfolio, company-reported
global sales and Datamonitor forecast, ($ billion), 2008- 2014
- Figure: Importance of Enbrel within the Wyeth and Amgen portfolios,
company-reported global sales and Datamonitor forecast, ($ billion), 2008- 2014
- Figure: Importance of Remicade within the Schering-Plough and Johnson &
Johnson portfolios, company-reported global sales and Datamonitor forecast, ($
billion), 2009- 2014
- Figure: Psoriasis-specific sales split by delivery method across the seven
major markets ($m), 2004- 08
- Figure: Successful uptake of Dovobet showing some switch from Dovonex in
the seven major markets ($m), 2005- 08
- Figure: Topical vitamin derivatives and corticosteroids by formulation in
the seven major markets ($m), 2005- 2018
- Figure: Vitamin D analog structures
- Figure: US psoriasis-specific biologic sales ($m), 2008- 2018
- Figure: Remicade price cut and recovery in Japan ($/SU), 2008
- Figure: Scenario A: US psoriasis-specific sales ($m), 2008-2018
- Figure: Scenario B: US psoriasis-specific sales ($m), 2008-2018
- Figure: Scenario C: US psoriasis-specific sales ($m), 2008- 2018
|
Related Report
|
View Cart
